SDGR vs RXRX
SDGR and RXRX side by side — valuation & fundamentals (public data).
Key statistics
| Metric | SDGRSchrodinger, Inc. | RXRXRECURSION PHARMACEUTICALS, INC. |
|---|---|---|
| Revenue | $254.91M(TTM) | — |
| Revenue growth (YoY) | 23.3% | 26.9% |
| Net income | -$103.48M(TTM) | — |
| Earnings growth (YoY) | 44.8% | -39.1% |
| EPS, diluted | $-1.40(TTM) | — |
| EBIT margin | -65.2% | -867.9% |
| ROE | -32.9% | -62.9% |
| ROIC | — | -174.7% |
| 1y total return | -21.7% | -42.6% |
Figures from SEC filings · for reference only · not investment advice
$10,000 투자 성장: SDGR vs RXRX
| 지표 | SDGR | RXRX |
|---|---|---|
| 최종 가치 | $2.0K | $1.1K |
| 총수익률 | -79.9% | -89.4% |
| CAGR | -26.1% | -34.5% |
| 변동성 | 62.4% | 92.9% |
| 샤프 | -0.24 | -0.06 |
| 소르티노 | -0.36 | -0.09 |
| 최대 낙폭 | -86.0% | -93.1% |
공통 거래일 1331일 기준, 2021-04-16 → 2026-08-04 · 무위험수익률 3.91% (현재 단기 국채 금리, 고정 적용)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)